Key Takeaways Morgan Stanley downgraded and cut the price target on Novo Nordisk stock, citing GLP-1 concerns. The analysts also raised doubts about the effectiveness of the drugmaker's experimental treatment for Alzheimer's disease. An analyst's concerns about demand for Novo Nordisk’s blockbuster weight-loss drugs is weighing on the drugmaker's shares to start the week. Why This Matters to You Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. U.S.-listed shares of Novo Nordisk have lost a third of their value this year.